

18th Annual Massachusetts Prostate Cancer Symposium

Fact, Fiction and the Future

FRIDAY, MAY 15, 2015

7:30 AM – 1:00 PM

Marriott Newton 2345 Commonwealth Avenue, Newton, Massachusetts

OPENING KEYNOTE (9:00AM)

Understanding and Implementing Immunotherapy for Prostate Cancer

Charles Drake, MD received his PhD in Immunology from the National Jewish Center for Immunology and his MD from the University of Colorado Health Sciences Center. He is currently an associate professor of oncology, urology and immunology at the Johns Hopkins School of Medicine and the co-director of the Prostate Cancer Multidisciplinary Clinic.



Following the presentation, Dr. Drake will host an educational session to further explore this topic.

SYMPOSIUM SCHEDULE

7:00–9:00AM	Registration and Breakfast Buffet
7:30	Early Bird Concurrent Educational Sessions
9:00	Opening Keynote
10:15	Concurrent Educational Sessions
11:30	Closing Panel
1:00PM	Symposium Adjourns

CLOSING PANEL in collaboration with AdMeTech Foundation (11:30AM)

Prostate Cancer Screening: Emerging scientific data and guidelines

This high level, multidisciplinary panel will discuss the most recent advances in prostate cancer screening. It will begin with a brief history and background on screening and then move into a presentation on guidelines and controversies based on emerging scientific data. Panelists will then engage in a general discussion followed by Q&A from the audience.

CME and CEU credits are available for medical professionals who attend this session.

Sponsored in part by an Educational Grant from the AdMeTech Foundation and the Massachusetts Department of Public Health



J. Jacques Carter, MD
Beth Israel Deaconess Medical Center



Neil E. Martin, MD, MPH
Dana-Farber/Brigham and Women's Cancer Center



Mark Pomerantz, MD,
Dana-Farber Cancer Institute



Andrew Vickers, Ph.D.
Memorial Sloan Kettering Cancer Center



Moderator:
Faina Shtern, MD
AdMeTech Foundation

1.5 CMEs & CEUs available for physicians, nurse practitioners and nurses!

The Massachusetts Prostate Cancer Coalition (MPCC)

educates, connects, and supports men-at-risk, newly diagnosed individuals, survivors, and their families. It also connects organizations and professionals in Massachusetts that seek to conquer and cure prostate cancer.

The Symposium has been held annually since 1997, averaging more than 300 attendees each year. More than 6400 people, in the aggregate, have attended the annual symposium.

EDUCATIONAL SESSIONS

7:30 AM – 8:30 AM (Concurrent Educational Sessions)

PSA Rising and Clinical Trials

The session will discuss the implications of rising PSA levels after surgery or radiation therapy or even both treatments. PSA doubling time, diagnostic work ups, possible therapeutic modalities and clinical trials will also be discussed.

Glenn Bubley, MD, Beth Israel Deaconess Medical Center

PSA Testing: Shared decision-making

This session will highlight the latest Decision Aid tools developed to help men work with their providers to make informed decisions about PSA testing.

Mark Kennedy, Executive Director, MPCC

SAVE THE DATE
June 24, 2015, 6:00pm



Presentation of the Jack Colbert Award to Dr. J. Jacques Carter

Reception at the Downtown Harvard Club

This year's recipient is **J. Jacques Carter, MD, MPH** who is on the staff of the Beth Israel Deaconess Medical Center, an assistant professor at Harvard Medical School, and the medical director of the Prostate Cancer Screening and Education Program at the Dana-Farber Cancer Institute.

The Jack Colbert Memorial Award is presented periodically, at the discretion of the MPCC board of directors to a distinguished individual in the medical community who has significantly advanced the fight to conquer and cure prostate cancer through research and/or practice.

Previous recipients of the Jack Colbert Award are:

- 2013 Matthew R. Smith, MD, Ph.D.
- 2011 Richard K. Babayan, MD
- 2010 William U. Shipley, MD
- 2009 Glenn J. Bubley, MD
- 2008 Philip W. Kantoff, MD

10:15–11:15 AM (Concurrent Educational Sessions)

Community Perceptions about Prostate Cancer: Creating a sustainable tool for community health

This videotaped panel session will address prevailing perceptions about diagnosis, treatment, recurrence and late stage prostate cancer in communities with predominantly high-risk populations to create a sustainable tool for community health.

J. Jacques Carter, MD Beth Israel Deaconess Medical Center

Aymen Elfiky, MD, Dana-Farber Harvard Cancer Center

Mark Kennedy, Executive Director, MPCC

Quoc-Dien Trinh, MD, Brigham and Women's Hospital, Dana-Farber/Harvard Cancer Center

Moderator: **Christopher Lathan**, MD, MS, MPH, Dana-Farber Cancer Institute

Imaging Advances in Prostate Cancer

This session will outline the recent advances in MRI that have led to improved detection of clinically significant disease. The session will focus on how these new MRI techniques are applied in patients with prostate cancer and pertinent points on the inherent advantages and limitations will be discussed.

Mukesh Harisinghani, MD, Massachusetts General Hospital

The Inheritability of Prostate Cancer

The session will address family history and ancestry as relates to risk of prostate cancer, and will review recent findings explaining the underlying heritability of risk.

Mark Pomerantz, MD, Dana-Farber Cancer Institute

Quality of Life After Prostate Cancer: Beyond erections

Effective treatments for erectile dysfunction and urinary leakage are available to men after treatment for prostate cancer. However, even after these treatments, some men may experience persistent sexual or urinary problems that affect quality of life. We will discuss strategies to overcome problems with orgasm, urinary leakage during intercourse, and overactive bladder.

Ravi Kacker, MD, Men's Health Boston

Understanding and Implementing Immunotherapy for Prostate Cancer: Continuing the conversation

A continuation of Dr. Charles Drake's opening keynote address.

PRESENTERS

Glenn Bubley, MD, a member of the MPCC Medical Advisory Committee, has been the director of a multi-disciplinary genitourinary cancer program dealing primarily with prostate biology at the Beth Israel Deaconess Medical Center since 1988. In 2009, MPCC honored him with the Jack Colbert Award.

J. Jacques Carter, MD is the medical director of the Prostate Cancer Screening and Education Program at the Dana-Farber Cancer Institute and is an assistant professor of medicine at Harvard Medical School. He is the 2015 recipient of MPCC's Jack Colbert Memorial Award.

Charles Drake, MD is associate professor of oncology, urology and immunology at the Johns Hopkins School of Medicine and the co-director of the Prostate Cancer Multidisciplinary Clinic.

Aymen Elfiky, MD, MA, MPH is a medical oncologist and instructor in medicine at Harvard Medical School. He is affiliated with the Dana-Farber Cancer Institute and Brigham and Women's Hospital.

Mukesh G. Harisinghani, MD is director of abdominal MRI at Massachusetts General Hospital and professor of radiology at Harvard Medical School.

Ravi Kacker, MD is a urologist and clinical instructor at Harvard Medical School. He is on the staff of Men's Health Boston and a part-time instructor in surgery at Beth Israel Deaconess Medical Center

Mark Kennedy, MBA is the executive director of the Massachusetts Prostate Cancer Coalition. Previously he served as manager of Men's Health Programs for Dana-Farber's Community Benefits Office. Working with healthcare providers, Kennedy delivered prostate cancer educational interventions and is developing prostate cancer clinical practice guidance to standardize service protocols for high-risk men.

Neal Martin, MD is assistant professor of radiation oncology at Harvard Medical School and the Dana-Farber/Brigham and Women's Cancer Center. His research has focused on molecular markers related to prognosis and prediction for prostate cancer.

Mark Pomerantz, MD is a medical oncologist at the Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School.

Faina Shtern, MD is the president and CEO of AdMeTech, whose mission is to provide unique and critically needed international leadership for expediting the development and implementation of advanced diagnostic tools for improved prevention, early detection and treatment of prostate cancer.

Quoc-Dien Trinh, MD is assistant professor of surgery at Harvard Medical School and is affiliated with the Dana-Farber Cancer Institute and with the Center for Surgery and Public Health at Brigham and Women's Hospital.

Andrew Vickers, Ph.D. is attending research methodologist at Memorial Sloan Kettering Cancer Center. His research falls into three broad areas: randomized trials, surgical outcomes research and molecular marker studies. A particular focus of his work is the detection and initial treatment of prostate cancer.

SPONSORS

Many thanks to this year's generous sponsors.

Massachusetts Department of Public Health

Massachusetts Prostate Cancer Coalition

Beth Israel Deaconess Medical Center

Dana-Farber Cancer Institute

The Barron Center for Men's Health – Mount Auburn Hospital

Peter Lacallade

Allen Snyder

Hall Swaim

Robert Kretschmar

Kirk Neison

Avi Nelson

Garth Greimann

EDUCATIONAL GRANTS

The 18th Annual Symposium is supported, in part, by educational grants from:

AdMeTech Foundation

Genentech, Inc.

EXHIBITOR TABLES

The exhibitors provide an array of pertinent information on prostate cancer resources. Please visit each table to learn about the medical and on-going support systems available.

AdMeTech Foundation

American Cancer Society

Beth Israel Deaconess Medical Center

Boston Prostate Cancer Walk

Cancer Support Community – Massachusetts South Shore

Janssen Biotech, Inc.

Massachusetts Prostate Cancer Coalition

Prostate Health Education Network

MASSACHUSETTS PROSTATE CANCER COALITION

c/o Green Associates, 200 Lincoln St., #201, Boston, MA 02111
www.masspcc.org

SYMPOSIUM PLANNING COMMITTEE

Lynn A. Basilio
American Cancer Society
Anita Christie
Massachusetts Department of Public
Health
Thomas L. Farmer
Judy Green
Massachusetts Prostate Cancer
Coalition
Mark Kennedy
Massachusetts Prostate Cancer
Coalition
Jane Matlaw
Beth Israel Deaconess Medical Center
Tiffany Nagle
Cullari Communications Global
Dalton A. Skerritt
Center for the Elimination of Health and
Social Inequities and Disparities
(CEHSID)
Matthew R. Smith, MD
Massachusetts General Hospital
Allen L. Snyder III
Northwestern Mutual Life Financial
Network
C. Hall Swaim
WilmerHale, LLP
William Tinney

BOARD OF DIRECTORS

C. Hall Swaim, Esq., president
WilmerHale LLP
Allen L. Snyder III, chairman
Northwestern Mutual Life Financial
Network
Garth Greimann, secretary & treasurer
Berkshire Partners LLC
Charles Austin
Lynn A. Basilio
American Cancer Society
Bryan Calder
U.S. Bank
John Carberry
Oppenheimer Multifamily Housing
& Healthcare Finance
Jason A. Efstathiou, MD
Massachusetts General Hospital
Neal F. Finnegan
Clover Capital and Consulting
Robert Kretschmar
Global Capital Resources, Inc.
Tiffany Nagle
Cullari Communications Global
C. Kirk Neison
Avi Nelson
Dalton A. Skerritt
Center for the Elimination of Health and
Social Inequities and Disparities
(CEHSID)

EXECUTIVE DIRECTOR

Mark Kennedy, MBA

DIRECTORS EMERITI

Arnold Barron
Bud Collins
Thomas L. Farmer
Robert S. Lyons
Janet McGrail Spillane
William R. Whitmore

MEDICAL ADVISORY COMMITTEE

Richard K. Babayan, MD
Boston Medical Center
Glenn J. Bubley, MD
Beth Israel Deaconess Medical Center
J. Jacques Carter, MD, MPH
Beth Israel Deaconess Hospital
Jason R. Gee, MD
Lahey Clinic Medical Center
Philip W. Kantoff, MD
Dana-Farber/Harvard Cancer Center
John P. Long, MD
Newton-Wellesley Hospital
Tufts University School of Medicine
Paul Nguyen, MD
Brigham and Women's Hospital
Oliver A. Sartor, MD
Tulane University School of Medicine
William U. Shipley, MD
Massachusetts General Hospital
Matthew R. Smith, MD
Massachusetts General Hospital
Mary-Ellen Taplin, MD
Dana-Farber Cancer Institute
Ingolf A. Tuerk, MD, Ph.D.
St. Elizabeth's Medical Center